These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32193463)

  • 1. Author Correction: DNA methylation landscape of triple-negative ductal carcinoma in situ (DCIS) progressing to the invasive stage in canine breast cancer.
    Beetch M; Harandi-Zadeh S; Yang T; Boycott C; Chen Y; Stefanska B; Mohammed SI
    Sci Rep; 2020 Mar; 10(1):5370. PubMed ID: 32193463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Author Correction: Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature.
    Li JW; Zhang K; Shi ZT; Zhang X; Xie J; Liu JY; Chang C
    Sci Rep; 2020 Mar; 10(1):4468. PubMed ID: 32144323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.
    Johnson KC; Koestler DC; Fleischer T; Chen P; Jenson EG; Marotti JD; Onega T; Kristensen VN; Christensen BC
    Clin Epigenetics; 2015; 7(1):75. PubMed ID: 26213588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.
    Rane SU; Mirza H; Grigoriadis A; Pinder SE
    Breast Cancer Res Treat; 2015 Aug; 153(1):101-21. PubMed ID: 26255059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.
    Ni Q; Stevic I; Pan C; Müller V; Oliveira-Ferrer L; Pantel K; Schwarzenbach H
    Sci Rep; 2019 Dec; 9(1):18700. PubMed ID: 31804497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y.
    Cancer; 2019 Apr; 125(7):1200. PubMed ID: 30875106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
    Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
    Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Author Correction: Quantitative proteomic analysis of enhanced cellular effects of electrochemotherapy with Cisplatin in triple-negative breast cancer cells.
    Mittal L; Aryal UK; Camarillo IG; Ferreira RM; Sundararajan R
    Sci Rep; 2019 Dec; 9(1):19124. PubMed ID: 31819154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Author Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
    Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
    Nat Nanotechnol; 2020 Apr; 15(4):342. PubMed ID: 31953520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Author Correction: Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
    Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
    Sci Rep; 2020 Jan; 10(1):1907. PubMed ID: 32005891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
    Hybiak J; Domagala P; Domagala W
    Pol J Pathol; 2018; 69(4):347-355. PubMed ID: 30786684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
    Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
    Nat Commun; 2020 Jan; 11(1):673. PubMed ID: 31996688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.
    Miligy IM; Toss MS; Shiino S; Oni G; Syed BM; Khout H; Tan QT; Green AR; Macmillan RD; Robertson JFR; Rakha EA
    Br J Cancer; 2020 Nov; 123(10):1584. PubMed ID: 32939057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
    Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
    Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.